Overview

• Health science solutions provider's Q1 revenue rose 7% yr/yr, slightly beating analyst expectations

• Adjusted EPS for Q1 beat analyst expectations

• Company to divest China Immunodiagnostics business, representing about 6% of 2025 revenue

Outlook

• Revvity sees 2026 pro forma revenue of $2.81-$2.84 bln

• Company expects 2026 pro forma organic revenue growth of 3%-4%

• Revvity forecasts 2026 pro forma adjusted EPS of $5.20-$5.30

Result Drivers

• ORGANIC GROWTH - Co said organic revenue growth and adjusted EPS exceeded internal expectations, citing strong execution across teams, per CEO Prahlad Singh

• SEGMENT PERFORMANCE - Diagnostics revenue grew 8% yr/yr with 4% organic growth and 9% pro forma organic growth; Life Sciences revenue grew 6% with 3% organic growth

• PORTFOLIO OPTIMIZATION - Co said its disciplined approach to portfolio optimization, including the planned divestiture of China Immunodiagnostics, positions it to capitalize on market conditions

Company press release: ID:nBw5lrVdha

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 Revenue	Slight Beat*	$711.12 mln	$704.99 mln (12 Analysts)
Q1 Adjusted EPS	Beat	$1.04	$1.02 (15 Analysts)
Q1 Adjusted EPS continuing operations		$0.40

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 10 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

• Wall Street's median 12-month price target for Revvity Inc is $110.00, about 27.2% above its May 4 closing price of $86.51

• The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 20 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.